Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 16.00 is 56% above its 5-year average of 10.25, around the middle of its 5-year range (1.02–45.15).
As of the fiscal period ended Tuesday, June 30, 2026. 3.77% below its 12-month average of 16.63.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.00.
CURRENT RATIO
16.00
CURRENT RATIO AVG TTM
16.63
CURRENT RATIO AVG 3Y
9.20
CURRENT RATIO AVG 5Y
10.25
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-3.77%
CURRENT VS 3Y AVG
+73.92%
CURRENT VS 5Y AVG
+56.16%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.54
median of 732 covered companies
CURRENT VS SECTOR MEDIAN
+351.32%
vs the sector median at left
Eupraxia Pharmaceuticals Inc.
Market Cap
$267.51M
Current Ratio
16.00
TTM Avg
16.63
3Y Avg
9.20
5Y Avg
10.25
Market Cap
$267.83M
Current Ratio
8.88
TTM Avg
8.27
3Y Avg
7.75
5Y Avg
6.94
Market Cap
$266.71M
Current Ratio
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
Market Cap
$267.87M
Current Ratio
4.50
TTM Avg
8.35
3Y Avg
6.79
5Y Avg
6.91
Market Cap
$261.87M
Current Ratio
13.89
TTM Avg
8.37
3Y Avg
7.38
5Y Avg
15.00
Market Cap
$273.53M
Current Ratio
9.24
TTM Avg
7.84
3Y Avg
8.19
5Y Avg
10.90
Market Cap
$277.05M
Current Ratio
9.22
TTM Avg
6.22
3Y Avg
4.84
5Y Avg
4.06
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $267.51M | 16.00 | 16.63 | 9.20 | 10.25 |
| OraSure Technologies, Inc. (OSUR)vs › | $267.83M | 8.88 | 8.27 | 7.75 | 6.94 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $266.71M | 15.82 | 24.04 | 14.70 | 12.06 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.87M | 4.50 | 8.35 | 6.79 | 6.91 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $261.87M | 13.89 | 8.37 | 7.38 | 15.00 |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | 24.26 | 16.09 | 10.56 | 7.83 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $273.53M | 9.24 | 7.84 | 8.19 | 10.90 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | 9.22 | 6.22 | 4.84 | 4.06 |
| AC Immune S.A. (ACIU)vs › | $256.77M | 0.93 | 1.36 | 5.78 | 8.29 |
| Fate Therapeutics, Inc. (FATE)vs › | $277.46M | 4.85 | 6.69 | 6.56 | 6.64 |
Current Ratio
16.00
Quick Ratio
16.00
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 16.00 |
| 2026-03-31 | 19.30 |
| 2025-12-31 | 15.12 |
| 2025-09-30 | 23.98 |
| 2025-06-30 | 8.72 |
| 2025-03-31 | 13.00 |
| 2024-12-31 | 11.10 |
| 2024-09-30 | 4.17 |
| 2024-06-30 | 2.11 |
| 2024-03-31 | 1.95 |
| 2023-12-31 | 1.02 |
| 2023-09-30 | 1.75 |
| 2023-06-30 | 1.35 |
| 2023-03-31 | 8.82 |
| 2022-12-31 | 6.08 |
| 2022-09-30 | 13.66 |
| 2022-06-30 | 10.13 |
| 2022-03-31 | 21.10 |
| 2021-12-31 | 13.49 |
| 2021-09-30 | 12.03 |
| 2021-06-30 | 45.15 |
| 2021-03-31 | 4.21 |
| 2020-12-31 | 0.05 |
| 2020-09-30 | 0.03 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.13 |
| 2019-09-30 | 0.00 |
